

Glucose Level Awareness (using self-monitoring of blood glucose [SMBG] and continuous glucose monitoring [CGM]) in Diabetes Study

Submission date 18/01/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 18/02/2011	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 18/07/2016	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr John New

Contact details
Salford Royal NHS Foundation Trust, Stott Lane,
Salford
United Kingdom
M6 8HD

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
ADC-PMR-NAV-10009

Study information

Scientific Title

Glucose Level Awareness (using self-monitoring of blood glucose [SMBG] and continuous glucose monitoring [CGM]) in Diabetes Study: a multicentre randomised controlled three-arm study

Acronym

GLADIS

Study objectives

To demonstrate clinical benefit of continuous glucose monitoring (CGM) relative to self-monitoring of blood glucose (SMBG).

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. UK: Sheffield Research Ethics Committee, 21/12/2010, ref: 10/H1308/77
2. Germany: Stuttgart Ethics Committee, 02/12/2010, ref: F-2010-090

Study design

Multicentre randomised controlled three-arm study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Diabetes

Interventions

Following a 20 day masked (baseline) period using the Freestyle Navigator subjects will be randomised into one of 3 groups for the next 80 days:

1. The first group will wear the FreeStyle Navigator for the remaining duration of the study
2. The second group will wear the FreeStyle Navigator with glucose alarms switched off
3. The third (control) group will manage their blood glucose with standard SMBG and use a FreeStyle Navigator masked for two, 20-day periods between 40 to 60 days and 80 to 100 days

For all 3 groups, subjects will complete Quality of Life Questionnaires and have HbA1c measurements at both baseline and day 100.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Time spent outside of glucose target: no alarms versus SMBG (days 80 - 100)

Secondary outcome measures

1. Time spent outside of glucose target: no alarms versus CGM (days 80 - 100)
2. Time spent outside of glucose target: CGM versus SMBG (days 80 - 100)
3. Time spent outside of glucose target (days 40 - 60)
4. HbA1c
5. Average glucose (days 40 - 60 and 80 - 100)
6. Glucose variability (days 40 - 60 and 80 - 100)
7. Quality of life measures
8. Adverse events

Overall study start date

31/01/2011

Completion date

01/05/2012

Eligibility**Key inclusion criteria**

Inclusion criteria as of 13/03/2012:

1. Subject with type 1 or type 2 diabetes on multiple daily injections (MDI) (3 or more insulin injections per day) or continuous subcutaneous insulin infusion (CSII) for greater than 6 months prior to study enrolment
2. Aged 18 - 65 years, either sex and, in the Investigator's opinion, thought technically capable of using CGM
3. HbA1c between 7% and 11% (inclusive) for previous HbA1c test obtained within 3 months prior to enrolment
4. Subject reporting testing of blood glucose an average of 2 - 7 times per day

Previous inclusion criteria

1. Subject with type 1 or type 2 diabetes on multiple daily injections (MDI) (3 or more insulin injections per day) or continuous subcutaneous insulin infusion (CSII) for greater than 1 year prior to study enrolment
2. Aged 18 - 65 years, either sex and, in the Investigator's opinion, thought technically capable of using CGM
3. HbA1c between 7.5% and 10% (inclusive) for previous HbA1c test obtained within 3 months prior to enrolment
4. Subject reporting testing of blood glucose an average of 2 - 7 times per day

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

150

Key exclusion criteria

1. Subject has known allergy to medical grade adhesives
2. Subject has concomitant disease or condition that influences metabolic control or, in the investigators opinion, may compromise patient safety
3. Subject is participating in another study of a glucose monitoring device or drug that could affect glucose measurements or glucose management
4. Subject is currently using another continuous glucose monitoring device or has used real-time continuous glucose monitoring in the last 6 months
5. Subject is pregnant/planning to become pregnant within the planned study duration

Date of first enrolment

31/01/2011

Date of final enrolment

01/05/2012

Locations

Countries of recruitment

England

Germany

United Kingdom

Study participating centre

Salford Royal NHS Foundation Trust

Stott Lane

Salford

United Kingdom

M6 8HD

Sponsor information

Organisation

Abbott Diabetes Care Ltd (UK)

Sponsor details

c/o Liz Phipps
Range Road
Witney
United Kingdom
OX29 0YL

Sponsor type

Industry

Website

<http://www.abbottdiabetescare.co.uk/>

ROR

<https://ror.org/03wnay029>

Funder(s)**Funder type**

Industry

Funder Name

Abbott Diabetes Care Ltd

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2015		Yes	No

